Mylan Gives Up Exclusivity For US Kaletra Rival
As AbbVie Stays Quiet Over Global IP Waiver
Mylan has waived US exclusivity rights to its generic version of AbbVie’s Kaletra, which is being investigated as a treatment for COVID-19, after a week of activity that has seen Israel move to compulsory-license generic versions of the brand and the originator step back from enforcing related intellectual property worldwide.
